Novavax
  • 14-Sep-2018 to 21-Dec-2018 (EST)
  • Quality Control
  • Gaithersburg, MD, USA
  • Full Time - Non-Exempt

At Novavax, a clinical-stage vaccine company, we are creating tomorrow's vaccines today! We seek to attract, develop, and retain talented people who share our passion for science, medicine, and human health. We foster an environment of teamwork and collaboration, built on a culture that values and appreciates its employees. We are a fast-paced company that provides employees with opportunities to achieve personal and professional goals while also maintaining a balance between work and personal life.

We are seeking a Quality Control Analyst to join our Quality Control team in Gaithersburg, MD. Qualified individuals will be responsible for performing all microbiology assays.

 

Responsibilities include but not limited to:

  • Performs routine environmental monitoring of GMP manufacturing suite
  • Performs facility water sampling
  • Performs TOC, conductivity, endotoxin and bioburden testing 
  • Performs sampling and analytical testing of raw materials
  • Performs media qualification testing
  • Receives, distributes, tracks and coordinates cGMP samples for testing
  • Prepares buffers and reagents
  • Keeps accurate testing records and assures that laboratory equipment has been calibrated, standardized, and monitored as appropriate
  • Logs and maintains all references and standards used for testing
  • Assists in the writing, reviewing, and editing of standard operating procedures

 

Minimum Requirements:

  • Bachelor's degree in biological science. Microbiology and/or virology experience a plus 
  • 0-3 years' experience in pharmaceutical, biologics, and/or vaccine manufacturing.
  • Knowledge and expertise in the principles and practices of current Good Manufacturing Practices (GMPs).
  • Knowledgeable in FDA regulations regarding the manufacturing of biologicals.
  • Good aseptic technique is essential for this position.
  • Microbiology and Environmental monitoring experience preferred
  • Proficient in Windows-based software to include Excel and Word.

 

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis. 

Our product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV) and Ebola virus (EBOV), and preclinical programs for Zika virus (ZIKV), seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates. 

Novavax, Inc. is headquartered in Gaithersburg, Maryland with additional facilities in Rockville, Maryland and Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease. 

Novavax, Inc. offers a base salary, annual bonus, stock options, professional career development/growth opportunities, and a comprehensive benefits package including medical, dental, vision, Rx, STD, LTD, Life, Optional Life, 401(k) plan.

 

Equal Opportunity Employer/Veterans/Disabled 

Novavax, Inc. is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.

Novavax
  • Apply Now

  • * Fields Are Required

    What is your full name?

    How can we contact you?

    I agree to ApplicantPro's Applicant Information Use Policy.*
  • Sign Up For Job Alerts!

  • Share This Page
  • Facebook Twitter LinkedIn Email
.
Logo Pipeline About us Investor News